Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122040623 | 12204062 | 3 | F | 201602 | 20160907 | 20160323 | 20160914 | EXP | US-PFIZER INC-2016166531 | PFIZER | 53.00 | YR | M | Y | 52.97000 | KG | 20160914 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122040623 | 12204062 | 1 | PS | RAPAMUNE | SIROLIMUS | 1 | Oral | 2 MG, DAILY | Y | L03350 | 21110 | 2 | MG | TABLET | |||||
| 122040623 | 12204062 | 2 | SS | RAPAMUNE | SIROLIMUS | 1 | Oral | 1 MG, DAILY | Y | 21110 | 1 | MG | TABLET | ||||||
| 122040623 | 12204062 | 3 | SS | RAPAMUNE | SIROLIMUS | 1 | Oral | 1 MG, DAILY | Y | 21110 | 1 | MG | TABLET | ||||||
| 122040623 | 12204062 | 4 | C | METOPROLOL ER | METOPROLOL SUCCINATE | 1 | Oral | 25 MG, 1X/DAY | 0 | 25 | MG | TABLET | QD | ||||||
| 122040623 | 12204062 | 5 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 10 MG, 1X/DAY | 0 | 10 | MG | QD | |||||||
| 122040623 | 12204062 | 6 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | DAILY; TWO 500 MG TABLETS DAILY BY MOUTH- TOTAL OF FOUR A DAY | 0 | TABLET | |||||||||
| 122040623 | 12204062 | 7 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | UNK UNK, DAILY (250 QD) | 0 | TABLET | ||||||||||
| 122040623 | 12204062 | 8 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | 500 MG, UNK | 0 | 500 | MG | TABLET | ||||||||
| 122040623 | 12204062 | 9 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | 250 MG, UNK | 0 | 250 | MG | TABLET | ||||||||
| 122040623 | 12204062 | 10 | C | CELLCEPT | MYCOPHENOLATE MOFETILMYCOPHENOLATE MOFETIL HYDROCHLORIDE | 1 | Oral | 500 MG, 2X/DAY | 0 | 500 | MG | TABLET | BID | ||||||
| 122040623 | 12204062 | 11 | C | CATAPRES | CLONIDINE HYDROCHLORIDE | 1 | Oral | 0.1 MG, 2X/DAY | 0 | .1 | MG | TABLET | BID | ||||||
| 122040623 | 12204062 | 12 | C | FERROUS SULFATE. | FERROUS SULFATE | 1 | Oral | 325 MG, 2X/DAY | 0 | 325 | MG | BID | |||||||
| 122040623 | 12204062 | 13 | C | TOPROL XL | METOPROLOL SUCCINATE | 1 | Oral | 25 MG, DAILY | 0 | 25 | MG | TABLET | |||||||
| 122040623 | 12204062 | 14 | C | CRESTOR | ROSUVASTATIN CALCIUM | 1 | Oral | 10 MG, 1X/DAY (BEDTIME) | 0 | 10 | MG | TABLET | QD | ||||||
| 122040623 | 12204062 | 15 | C | AUGMENTIN | AMOXICILLINCLAVULANATE POTASSIUM | 1 | Oral | 1 DF, 2X/DAY (AMOXICILLIN-CLAVULANATE 875-125 MG) (1 TAB, ORAL, EVERY 12 HOURS, X 7 DAYS) | 0 | 1 | DF | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122040623 | 12204062 | 1 | Renal transplant |
| 122040623 | 12204062 | 2 | Pancreas transplant |
| 122040623 | 12204062 | 4 | Hypertension |
| 122040623 | 12204062 | 5 | Hypertension |
| 122040623 | 12204062 | 6 | Kidney transplant rejection |
| 122040623 | 12204062 | 7 | Pancreas transplant rejection |
| 122040623 | 12204062 | 11 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122040623 | 12204062 | OT |
| 122040623 | 12204062 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122040623 | 12204062 | Anaemia | |
| 122040623 | 12204062 | Asthenia | |
| 122040623 | 12204062 | Blood iron decreased | |
| 122040623 | 12204062 | Chills | |
| 122040623 | 12204062 | Chronic kidney disease | |
| 122040623 | 12204062 | Contusion | |
| 122040623 | 12204062 | Decreased appetite | |
| 122040623 | 12204062 | Dehydration | |
| 122040623 | 12204062 | Ejection fraction decreased | |
| 122040623 | 12204062 | Fatigue | |
| 122040623 | 12204062 | Hepatic enzyme increased | |
| 122040623 | 12204062 | Hyperlipidaemia | |
| 122040623 | 12204062 | Hypertension | |
| 122040623 | 12204062 | Hypoalbuminaemia | |
| 122040623 | 12204062 | Hyponatraemia | |
| 122040623 | 12204062 | Hypotension | |
| 122040623 | 12204062 | Lymphoma | |
| 122040623 | 12204062 | Lymphoproliferative disorder | |
| 122040623 | 12204062 | Night sweats | |
| 122040623 | 12204062 | Product use issue | |
| 122040623 | 12204062 | Pyrexia | |
| 122040623 | 12204062 | Renal failure | |
| 122040623 | 12204062 | Sepsis | |
| 122040623 | 12204062 | Tachycardia | |
| 122040623 | 12204062 | Weight decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122040623 | 12204062 | 1 | 2000 | 0 | ||
| 122040623 | 12204062 | 3 | 20160410 | 0 | ||
| 122040623 | 12204062 | 4 | 199604 | 0 | ||
| 122040623 | 12204062 | 5 | 199604 | 0 | ||
| 122040623 | 12204062 | 6 | 1996 | 0 | ||
| 122040623 | 12204062 | 7 | 1996 | 0 | ||
| 122040623 | 12204062 | 10 | 20160411 | 0 | ||
| 122040623 | 12204062 | 11 | 199604 | 20160411 | 0 | |
| 122040623 | 12204062 | 12 | 20160317 | 0 | ||
| 122040623 | 12204062 | 13 | 20160411 | 0 |